Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Trial Evaluating the Efficacy and Safety of Aspirin and Lansoprazole in High-Risk Pregnant Women for the Prevention of Preterm Birth: A Biomarker-Enriched Design

NCT07337655 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07337655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Trial Evaluating the Efficacy and Safety of Aspirin and Lansoprazole in High-Risk Pregnant Women for the Prevention of Preterm Birth: A Biomarker-Enriched Design
Lead sponsor
Stanford University
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 30, 2032
Enrollment
670 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pre-term birth